Cathy Williams

2.0k total citations
22 papers, 939 citations indexed

About

Cathy Williams is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Cathy Williams has authored 22 papers receiving a total of 939 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 12 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Cathy Williams's work include Multiple Myeloma Research and Treatments (19 papers), Cancer Treatment and Pharmacology (8 papers) and Peptidase Inhibition and Analysis (6 papers). Cathy Williams is often cited by papers focused on Multiple Myeloma Research and Treatments (19 papers), Cancer Treatment and Pharmacology (8 papers) and Peptidase Inhibition and Analysis (6 papers). Cathy Williams collaborates with scholars based in United Kingdom, United States and Canada. Cathy Williams's co-authors include Tadeusz Robak, Jiřı́ Mayer, Martin J.S. Dyer, Andrzej Hellmann, Nedjad Losic, Anders Österborg, Magdalena Piotrowska, Stephan Stilgenbauer, Marek Trněný and Charlotte Russell and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Cathy Williams

21 papers receiving 925 citations

Peers

Cathy Williams
Comparison fields: 5 of 55
  • Hematology 486
  • Oncology 400
  • Genetics 374
  • Pathology and Forensic Medicine 348
  • Molecular Biology 328
Replace Liana Gercheva with:
Liana Gercheva Bulgaria
Christine I. Chen Canada
Olivier Fitoussi France
Emma Das‐Gupta United Kingdom
Giulia Benevolo Italy
Tommy Fu United States
Al‐Ola Abdallah United States
J. Thaler Austria
Bradley Augustson Australia
Karthik Ramasamy United Kingdom
Liana Gercheva Bulgaria View profile →
Citations per field, relative to Cathy Williams
Cathy Williams · 1×
Citations per year, relative to Cathy Williams
Cathy Williams · 1×

Countries citing papers authored by Cathy Williams

Since Specialization
Citations

This map shows the geographic impact of Cathy Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cathy Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cathy Williams more than expected).

Fields of papers citing papers by Cathy Williams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cathy Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cathy Williams. The network helps show where Cathy Williams may publish in the future.

Co-authorship network of co-authors of Cathy Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Cathy Williams. A scholar is included among the top collaborators of Cathy Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cathy Williams. Cathy Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study
2022 ·Bone Marrow Transplantation ·John A. Snowden, Sam H. Ahmedzai, Angela Cox, David A. Cairns, A. John Ashcroft, Cathy Williams, Jamie Cavenagh, Anna Hockaday, Julia Brown, Ian W. Brock, T. C. M. Morris, Gordon Cook
0
2
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
2018 ·Trials ·Alina Striha, A. John Ashcroft, Anna Hockaday, David A. Cairns, (unknown), (unknown), Cathy Williams, John A. Snowden, Mamta Garg, Jamie Cavenagh, Kwee Yong, Mark T. Drayson, Roger G. Owen, Mark Cook, Gordon Cook
5
3
Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial
2018 ·Blood ·Gordon Cook, Christopher Parrish, Kwee Yong, Jamie Cavenagh, John A. Snowden, Mark T. Drayson, Mamta Garg, David A. Cairns, John Ashcroft, Alina Striha, Anna Hockaday, Ruth M. de Tute, Roger G. Owen, Cathy Williams, Mark Cook
4
4
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial
2016 ·Biology of Blood and Marrow Transplantation ·Christopher Parrish, Curly Morris, Cathy Williams, David A. Cairns, Jamie Cavenagh, John A. Snowden, John Ashcroft, Jim Cavet, Hannah Hunter, Jenny Bird, A. Chalmers, Julia Brown, Kwee Yong, Steve Schey, (unknown), Gordon Cook
6
5
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
2016 ·The Lancet Haematology ·Gordon Cook, A. John Ashcroft, David A. Cairns, Cathy Williams, Julia Brown, Jamie Cavenagh, John A. Snowden, Christopher Parrish, Kwee Yong, Jim Cavet, Hannah Hunter, Jenny Bird, Guy Pratt, (unknown), (unknown), Sheila J.M. O’Connor, Mark T. Drayson, Anna Hockaday, T. C. M. Morris
96
6
A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial
2016 ·Blood ·Rakesh Popat, Sarah Brown, (unknown), Fiona Collinson, Louise Flanagan, Cathy Williams, Kwee Yong, Gordon Cook, Matthew Jenner, Martin Kaiser, Jim Cavet, Dima El‐Sharkawi, (unknown), Eric Low, Gareth J. Morgan, Faith E. Davies
5
7
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial
2015 ·British Journal of Haematology ·Steve Schey, Sarah Brown, (unknown), Kwee Yong, Cathy Williams, Faith E. Davies, Gareth J. Morgan, Jamie Cavenagh, Gordon Cook, Mark Cook, Guillermo Ortí, Curly Morris, (unknown), Louise Flanagan, Walter M. Gregory, James Cavet
16
8
Velcade, Vorinostat and Dexamethasone (V2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial
2015 ·Blood ·Matthew Jenner, (unknown), Sarah Brown, Louise Flanagan, (unknown), Charlotte Pawlyn, Cathy Williams, Faith E. Davies
1
9
A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial
2015 ·Blood ·Gordon Cook, Cathy Williams, David A. Cairns, Anna Hockaday, Jamie Cavenagh, John A. Snowden, Christopher Parrish, Kwee Yong, Jim Cavet, Hannah Hunter, Jennifer M. Bird, Guy Pratt, (unknown), (unknown), Sheila J.M. O’Connor, John Ashcroft, Julia Brown, Curly Morris
4
10
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma
2014 ·Health and Quality of Life Outcomes ·Irina Proskorovsky, Philip Lewis, Cathy Williams, Karin Jordan, Charalampia Kyriakou, Jack Ishak, Faith E. Davies
52
11
A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
2014 ·American Journal of Hematology ·Robert Z. Orlowski, Liana Gercheva, Cathy Williams, Heather J. Sutherland, Tadeusz Robak, Tamás Masszi, Vesselina Goranova‐Marinova, Meletios Α. Dimopoulos, James D. Cavenagh, Ivan Špıčka, Ângelo Maiolino, А. Н. Суворов, Joan Bladé, Olga Samoylova, Thomas A. Puchalski, Manjula Reddy, Rajesh Bandekar, Helgi van de Velde, Hong Xie, (unknown)
115
12
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
2014 ·The Lancet Oncology ·Gordon Cook, Cathy Williams, Julia Brown, David A. Cairns, Jamie Cavenagh, John A. Snowden, A. John Ashcroft, (unknown), Christopher Parrish, Kwee Yong, Jim Cavet, (unknown), Jenny Bird, A. Chalmers, Sheila J.M. O’Connor, Mark T. Drayson, T. C. M. Morris
95
13
The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial
2013 ·Blood ·John Ashcroft, Ruth M. de Tute, David A. Cairns, (unknown), Roger G. Owen, Andy C. Rawstron, Sheila J.M. O’Connor, Cathy Williams, John A. Snowden, Jamie Cavenagh, Christopher Parrish, Curly Morris, Julia Brown, Gordon Cook
2
14
A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial
2013 ·Blood ·Gordon Cook, Cathy Williams, David A. Cairns, (unknown), Jamie Cavenagh, John A. Snowden, Christopher Parrish, John Ashcroft, Kwee Yong, Jim Cavet, Hannah Hunter, Jennifer M. Bird, Sheila J.M. O’Connor, Julia Brown, Curly Morris
1
15
Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma
2013 ·Blood ·Stephen Schey, Kwee Yong, Cathy Williams, Faith E. Davies, Gareth J. Morgan, James D. Cavenagh, Gordon Cook, Mark Cook, (unknown), Sarah Brown, Louise Flanagan, Walter M. Gregory, Jim Cavet
1
16
Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study
2013 ·Supportive Care in Cancer ·Karin Jordan, Irina Proskorovsky, Philip Lewis, Jack Ishak, Krista Payne, (unknown), Charalampia Kyriakou, Cathy Williams, Sarah Peters, Faith E. Davies
100
17
Experience with Long-Term Lenalidomide (LEN) Treatment in the Clinical Setting: Results From the UK Revlimid® Treatment Continuation Scheme™ (TCS)
2012 ·Blood ·Cathy Williams, Mathew Simcock, (unknown), (unknown), Faith E. Davies
1
18
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
2010 ·Journal of Clinical Oncology ·William G. Wierda, Thomas J. Kipps, Jiřı́ Mayer, Stephan Stilgenbauer, Cathy Williams, Andrzej Hellmann, Tadeusz Robak, Richard R. Furman, Peter Hillmen, Marek Trněný, Martin J.S. Dyer, (unknown), Magdalena Piotrowska, Tomáš Kozák, Geoffrey Chan, Randy Davis, Nedjad Losic, (unknown), Charlotte Russell, Anders Österborg
413
19
Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab
2009 ·Clinical Lymphoma & Myeloma ·William G. Wierda, Thomas J. Kipps, Jiřı́ Mayer, Stephan Stilgenbauer, Cathy Williams, Andrzej Hellmann, Tadeusz Robak, Richard R. Furman, Peter Hillmen, Marek Trněný, Martin J.S. Dyer, (unknown), Magdalena Piotrowska, Tomáš Kozák, Geoffrey Chan, Randy Davis, Nedjad Losic, (unknown), Charlotte Russell, Anders Österborg
3
20
Multiple myeloma: Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma
2006 ·Gamal Sidra, Cathy Williams, Nigel H. Russell, (unknown), Bethan Myers, Jenny Byrne
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liana Gercheva Breakdown of academic impact, for papers by Christine I. Chen Breakdown of academic impact, for papers by Olivier Fitoussi Breakdown of academic impact, for papers by Emma Das‐Gupta Breakdown of academic impact, for papers by Giulia Benevolo Breakdown of academic impact, for papers by Tommy Fu Breakdown of academic impact, for papers by Al‐Ola Abdallah Breakdown of academic impact, for papers by J. Thaler Breakdown of academic impact, for papers by Bradley Augustson Breakdown of academic impact, for papers by Karthik Ramasamy
Rankless by CCL
2026